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Inhibition of immunoglobulin production by parathyroid hormone.
Implications in chronic renal failure. Available data indicate that B cell
proliferation is inhibited in chronic renal failure and this is due to excess
blood levels of PTH. This defect may also affect immunoglobulin
production. We examined production of IgG, 1gM and IgA by B cells
stimulated with Staphylococcus aureus Cowan I (SAC) or with
pokeweed mitogen (PWM) after eight days of culture and evaluated the
effect of PTH on this process in 34 hemodialysis patients and 44 normal
subjects. IgG, 1gM and IgA production by B cells from patients was
lower (P < 0.01) than by B cells from normal subjects. Both 1-34 and
1-84 PTH inhibited (P < 0.01) immunoglobulin production by B cells
from normal subjects and dialysis patients. However, this inhibitory
effect was evident in dialysis patients only with the higher dose of PTH.
The inhibition of immunoglobulin production by PTH occurred only
when the hormone was added at the initiation of the B cell culture.
Inactivation of PTH abolished its inhibitory effect on immunoglobulin
production. Agents that stimulate cAMP production (forskolin, cholera
toxin) and the cAMP analogue, 8-bromoadenosine 3',5' cyclic mono-
phosphate inhibited immunoglobulin production by B cells from both
normal and dialysis patients, and the degree of inhibition was not
different between the two groups. The calcium inophore A23 187 also
inhibited IgG, IgA and 1gM production by B cells from normal subjects
and dialysis patients; there was no significant difference in the degree of
inhibition between the two groups. The resting levels of cytosolic
calcium in B cells of dialysis patients was significantly (P < 0.01) higher
than that of B cells from normal subjects. The data show that: (1)
immunoglobulin production is impaired in dialysis patients; (2) B cells
of dialysis patients have elevated resting levels of cytosolic calcium; (3)
PTH inhibits IgG, IgA and 1gM production and this effect is at least
partly mediated by PTH-induced cAMP production and alterations in
cytosolic calcium into B cells; (4) this inhibitory effect is mediated by
events that affect initial stages of B cell proliferation and maturation; (5)
the requirement for high dose of PTH for its inhibitory effect on B cells
from dialysis patients is probably due to desensitization and/or down-
regulation of PTH receptors on B cells. The results are consistent with
the proposition that impaired immunoglobulin production by B cells
from dialysis patients is at least partly due to the state of secondary
hyperparathyroidism in these patients.
Certain data suggest that abnormalities in humoral immunity
exist in uremia [1—9]. These include reduced in vitro immuno-
globulin production by human B cells stimulated by pokeweed
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mitogen (PWM) [7, 8] or Staphylococcus aureus Cowan I (SAC)
[3, 6] and decreased response to typhoid 0 and H antigens [1,
9], tetanus toxoid [1], influenza vaccine [2] and hepatitis B
vaccine [5]. Also rabbits with acute uremia displayed impaired
response to bovine serum albumin [4]. In contrast, Stoloff et al
[10] found that 12 out of 13 azotemic patients had normal
antibody response to diphtheria toxoid, and Nelson [11] re-
ported that the antibody response of uremic rats immunized
with sheep red blood cells and Escherichia co/i 075 was normal.
It appears, therefore, that the majority of the reported data
supports the notion that antibody production in response to
many antigenic stimuli are impaired in patients with chronic
renal failure. The mechanisms responsible for such a defect are
not evident.
Studies in our laboratories have demonstrated that the human
B cell is a target for parathyroid hormone (PTH) in that both the
intact molecule of the hormone (1-84 PTH) and its aminotermi-
nal fragment (1-34 PTH) inhibited SAC-induced proliferation of
B cells from normal subjects [12]. Also PTH stimulated cyclic
AMP production by human B cells [12], suggesting the presence
of receptors for the hormone on these cells. Support for this
latter claim is provided by the studies of Bialasiewicz et al [13];
these authors demonstrated that B cells from patients with
Hodgkin's disease, acute leukemia, Burkitt's lymphoma or
thymic hyperplasia kept in culture had receptors for P1'H.
Patients with chronic renal failure have secondary hyperpara-
thyroidism [14] and elevated blood levels of PTH [14—16]. Since
PTH inhibits B cell proliferation [12], it is, theoretically, possi-
Me that the chronic exposure of the B cells in uremic patients to
excess PTH may adversely affect their ability to produce
immunoglobulins in response to antigenic stimulation. Such a
potential effect of PTH would provide, at least, a partial
explanation for the impaired humoral immunity in chronic renal
failure.
The present study examined the effect of PTH on antibody
production by human B cells obtained from normal subjects and
from dialysis patients and evaluated some of the mechanisms
that may underlie such an interaction between the hormone and
the B cell.
96
Methods
Thirty-four hemodialysis patients and 44 healthy subjects
were studied. Among the dialysis patients, there were 16
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Fig. 1. SAC and PWM-induced immunoglobulin production by B cells
from normal subjects (Q) and dialysis patients (. Each column
represents mean value, brackets denote I SE. *D < 0.01 and ** < 0.05
vs. normal subjects.
females and 18 males; their age ranged between 31 and 65 (51.8
1.9) years and the duration of the dialysis therapy between 2
and 180 months (45.1 10.5). None of the patients had
evidence of systemic diseases nor were they receiving medica-
tions known to affect the immune response. Among the healthy
volunteers, there were 13 females and 31 males and their age
ranged between 24 and 45 (33.3 1.0) years. The protocol of
the study was approved by the Institutional Review Board of
the Los Angeles County/University of Southern California
Medical Center.
Separation of peripheral blood mononuclear cells (PBMC)
A sample of 20 ml of peripheral venous blood was drawn
under sterile conditions into vacutainers containing 20 U of
preservative free heparin (GIBCO Laboratories, Grand Island,
New York, USA) per each 1.0 ml blood. Blood samples from
dialysis patients were collected before the dialysis procedure.
PBMC were isolated from heparinized blood by the density
gradient centrifugation at 400 g for 30 minutes at room temper-
ature on Ficoll-hypaque solution (Isolymph, Gallard-Schies-
inger, New York, USA) and washed twice (at 300 g for 10
minutes) with Hank's balanced salt solution (HBSS) containing
100 U/mi penicillin and 100 jsg/ml streptomycin (GIBCO). After
final wash, cells were suspended at a concentration of 2 x 106
cells/mi in growth medium RPM! 1640 (GIBCO) containing 10
mM HEPES buffer, antibiotics (100 U/mi penicillin and 100
/.LgJml streptomycin) and supplemented with heat-inactivated
10% fetal calf serum (FCS) (Irvine Scientific, Irvine, California,
* USA) and 2 mti L-glutamine (GIBCO). This is referred below
as culture medium. Viability of cells were assessed by trypan
blue exclusion and yielded 98% viable cells.
Reagents
Parathyroid hormone. Three preparations of PTH were used.
These included: (a) bovine intact molecule of PTH (1-84 P1'H)
purchased from Sigma Chemical Co. (St. Louis, Missouri,
USA) (b) synthetic bovine aminoterminal fragment of PTH
(1-34 PTH) purchased from Bachem (Torrance, California,
USA), and (c) inactivated 1-84 PTH. The inactivation of the
hormone was done by oxidation as follows: 10 to 15 sg of 1-84
PTH was dissolved in 60 tl 0.15 N acetic acid, and to this
solution 40 l of 30% H,02 was added. The solution was
incubated at 37°C for 45 minutes and the reaction was termi-
nated by freezing at —70°C and the product was recovered by
lyophylization. All preparations of PTH were dissolved in 100
m acetic acid and diluted with culture media to obtain the
desired concentrations (1 and 5 x iO— and 10_6 M for 1-84
P'I'H; iO and 106 M for 1-34 PTH; and 5 x l0 M for
inactivated 1-84 PTH). All solutions of PTH were filtered
through 0.22 pm cellulose acetate membrane filters (Coming
Glass Works, Corning, New York, USA) to ensure sterility and
were used within one day.
Staphylococcus aureus cowan strain I (SAC) and pokeweed
mitogen (PWM). SAC was obtained from Bethesda Research
Laboratory (Gaithersburg, Maryland, USA) and was prepared
by diluting whole formalinized bacteria with culture medium
and used at a final concentration of 1:50000 vol/vol, which was
established as optimal for our culture conditions. PWM was
purchased from GIBCO Laboratories and was diluted with
culture medium and used at a final concentration of 1:100
vollvol.
Forskolin, calcium ionophore (A23187), dimethylsulfoxide
(DM50), 8-bromoadenosine 3' ,5' cyclic monophosphate and
cholera toxin. Stock solution of forskolin (Boehringer, San
Diego, California, USA) was prepared in ethanol (5 mg/mi).
Calcium ionophore (Sigma) was dissolved in DMSO to a
concentration of 5 m. Further dilutions of these reagents were
made in a complete culture medium to achieve the following
concentrations: 20 pg/ml of forskolin and 0.5 M of calcium
ionophore. Twenty-five mg of 8-bromoadenosine 3'5' cyclic
monophosphate (Sigma) was dissolved in 0.58 ml of DMSO;
this stock solution was diluted 20 or 10 times with culture
medium. An aliquot of 10 sl of this solution was added to the
culture tube giving a final concentration of 100 or 200 M of
8-bromoadenosine 3'5' cyclic monophosphate. Cholera toxin
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Table 1. Effect of 1-84 and 1-34 PTH on SAC-induced or PWM-induced immunoglobulin production by B cells from normal subjects or
dialysis patients
1-84 PTH 1-34 PTH
No PTH l0 M 5 )< i0 M 10-6 M No PTH iO M 10-6 M
Normal subjects
1. Studies with SAC
IgG ng/ml(N = 8) 683 69 702 94 419 106° 368 78" 915 113 (n = 16) 711 91° 622 87k'
IgAng/ml(N= 10) 778 132 703 173 398 136b 384 116" 900 148(n = 14) 840 161 516 133b,d
1gM ng/ml (N = 7) 1253 240 1183 294 373 179" 443 152" 1211 132 (n = 14) 996 120 617 131LI
2. Studies with PWM
IgG ng/ml(N = 10) 854 161 698 95 561 123" 569 110" 1180 109(n = 16) 1085 108 974
IgA ng/ml (N = 7) 1311 211 1160 207 494 132" 433 104b 1376 194 (n = 13) 1110 144 935 130k
1gM ng/ml (N = 9) 937 113 818 168 253 73" 107 12"-° 1125 124 (n = 13) 918 97 810 99°
Dialysis patients
1. Studies with SAC
IgG ng/ml (N = 11) 509 117 511 132 416 107 347 109"
IgA ng/ml (N = 13)
1gM ng/m! (N 12)
456 104
288 73
577 163
321 112
374 71
172 64
267 66°-°
163 48b
2. Studies with PWM
IgGng/m!(N= 9) 436±87 451 108 440±67 393 65
IgA ng/ml (N = 12) 1089 138 1251 155 1124 101 830 126
1gM ng/ml (N = 11) 416 74 480 109 384 100 345 90
Data are presented as mean 1 SE.
a p < 0.05 vs No PTHb P < 0.01 vs No PTH
P < 0.05 vs 5 x l0 M PTHd P < 0.05 vs l0 M PTH
(No. C-3012, Sigma) was dissolved in distilled water (0.5 mg/mI)
and then diluted with the culture medium to obtain a final
concentration of 0.1 jsglml. Aliquots 25 d of this solution was
used in each culture tube.
Culture conditions and production of immunoglobulins
Lymphocytes were cultured for eight days in 5 ml Falcon test
tubes (Becton Dickinson, Oxnard, California, USA) placed in
humidified environment of 37°C and 5% CO2 in a water jacket
incubator (Forma Scientific, Marrietta, Ohio, USA). Each tube
contained 250 d of cell suspension (0.5 x l0 cells), 50 p1 of
SAC or PWM solutions, and 200 jd of PTH solution giving a
final volume of 500 p1. In studies with forskolin, calcium
ionophore, cholera toxin, or 8-bromoadenosine 3' ,5' cyclic
monophosphate, 25 p1 of the solutions of these agents were also
added to a final volume of 525 p1. In control culture studies
without PTH, mitogen, forskolin, calcium ionophore, cholera
toxin, or 8-bromoadenosine 3',5' cyclic monophosphate, the
solutions of these agents were replaced with equivalent vol-
umes of the culture media so that the final volumes of the
experimental and control studies were identical. All studies
were carried out in duplicates. In all these studies, the produc-
tion of the immunoglobulins (IgG, 1gM and IgA) was measured
after eight days of culture.
In five experiments, we examined the effect of PTH on 1gM
production when the hormone was added at different time of the
PBMC culture. In these experiments parallel culture studies
were carried out with SAC or PWM with and without 5 X 10
M 1-84 PTH; the hormone was added to the culture at the
beginning and at day 2, of the culture. Supernates were ob-
tained for the measurement of 1gM on days 2, 4, 6, 8 and 10 of
the culture from the control studies and from those with SAC or
PWM with and without PTH.
Measurements of immuno globulins
The concentrations of immunoglobulins (ng/ml) were mea-
sured by solid phase enzyme-linked immunoabsorbent assay
(ELISA) [17, 18]. Supernates removed from the culture tubes
were diluted 4 to 20 times with phosphate buffered saline (PBS)
(GIBCO) containing 0.5% of bovine serum albumin (BSA) and
0.05% Tween 20 (Sigma) and stored at —20°C until assay.
Samples of 100 p1 of stock of(1.0 mg of protein/mI) solution of
goat anti-human IgG, 1gM and IgA were diluted 1:1000 with
carbonate-bicarbonate buffer giving a concentration of 1.0 jsg of
protein/ml. Samples of 100 p1 of this solution were used to coat
flat bottomed 96-well microplate (Linbro/Titertek, Flow,
McLean, Virginia, USA). The plates were incubated for two
hours at 37°C. The antibody solution was then discarded and
the uncoated sites of the wells were blocked by the addition of
100 p1 of 1% bovine serum albumin dissolved in distilled water.
The plates were incubated for another 1.5 hours at 37°C. The
microplates were washed three times by soaking in 0.9% NacI
solution containing 0.05% Tween 20 for two minutes. Samples
of 100 .d of supernate of lymphocyte cultures were added to
each well and incubated for 1.5 hours at 37°C. Simultaneously,
100 p1 of standard solutions of the immunoglobulins in a
concentration of 1, 10, 25, 50, 75 and 100 ng protein/mi were
applied to the microplate so that each plate had its own standard
curve. The contents of the wells were then discarded and the
wells were washed three times with NaC1-Tween solution.
Samples of 100 Ll of the appropriate goat anti-human immuno-
globulin antibody conjugated with horseradish peroxidase
(Zymed Laboratories, San Francisco, California, USA) were
added to the wells. Stock solutions of the conjugated antibodies
were diluted with PBS containing 0.5% bovine serum albumin
and 0.05% Tween to 1:6000 for IgG, 1:2000 for 1gM and 1:2500
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Fig. 2. The effect of 1-84 PTH (5 X io- M) and its inactivation on SAC
and PWM-induced immunoglobulin production by B cells from normal
subjects. Symbols are: (LI) mitogen; (•) mitogen + PTH; ()mitogen
+ inactive PTH. Each column represents mean value of 6 studies
conducted simultaneously and brackets denote 1 SE. *P < 0.01 vs.
mitogen or mitogen and inactive PTH,
for IgA. The wells were incubated for 1.5 hours at 37°C, and the
contents were then discarded and wells washed three times with
NaC1-Tween solution. Samples of 100 d of 0-phenylene-
diamine dihydrochloride in citric buffer were added to the wells
which were left in the dark for 10 minutes. The reaction was
terminated by the addition of 100 d of 6 N H2S04. The optical
density of each well was determined with the use of an ELISA
Titertek multiscan reader (Dynatech Laboratories, Alexandria,
Virginia, USA). The actual concentrations of the various immu-
noglobulins in the supernate of the culture were determined
using the appropriate standard curve which was linear between
Table 2. Effect of 5
the culture on SAC o
X l0— M 1-84 PTH added at day 0 or day 2 of
r PWM-induced 1gM production by B cells from
normal subjects
Days of culture ng/ml
4 6 8 10
Studies with SAC
(N = 4)
No PTH 64 36 565 170 878 172 1106 191
PTHondayo l4±2a l50±120a 71±36a 216±77°
PTHonday2 56±32 372± 109 588± 141 695±88
Studies with PWM
(N =5)
No PTH 153 82 773 266 999 228 1164 207
PTH on day 0 II 1° 253 128° 328 238° 466 256°
PTHonday2 120±64 554± 161 644±128 882±230
Data are mean SE.
a P < 0.01 from No PTH or PTH on day 2
10 to 100 ng/ml. The preparation of the various PTH moieties
did not react with goat anti-human antibodies.
Measurements of cytosolic calcium [Ca2
PBMC were isolated from normal subjects and hemodialysis
patients by Ficoll-Hypaque fractionation as described above. B
cells were separated from PBMC using rosetting with immuno-
magnetic particles (Dynal Inc., Great Neck, New York, USA).
Samples of i0 PBMC in 1 ml of RPMI 1640 medium containing
5% FCS were incubated with 0.1 ml of anti-CD19 (Leu 12,
Becton Dickinson) monoclonal antibody for 40 minutes. All
procedures were carried at 4°C to reduce nonspecific binding of
antibodies. Cells were washed twice and centrifuged with
HBSS for 10 minutes at 300 g and the pellet resuspended in 0.1
ml of 5% FCS/RPMI 1640 medium. Ten microliters Dynabeads
M-450 coated with sheep anti-mouse IgG1 (Dynal) were added
to the pellet, gently mixed and incubated for 50 minutes. After
the incubation, cells were resuspended in 5 ml of 5% FCS/RPMI
1640 medium and kept in a Dynal magnetic particle concentra-
tor for two minutes; the supernatant containing non-rosetted
(non-B) cells was then discarded. The remaining rosetted cells
were resuspended in 5 ml of 5% FCS/RPMI 1640 medium and
the procedure for the removal of non-rosetted cells was re-
peated five times. After the last washing, cells were suspended
in 1 ml of 2% FCS/RPMI 1640 medium and kept overnight
(37°C, 5% C02) to detach Dynabeads from B cells. This
separation procedure resulted in >95% pure preparation of B
cells was estimated by flow cytometry after staining with
fluorescein-conjugated anti-CD2O (Leu 16, Becton Dickinson)
monoclonal antibody. Detached magnetic particles were re-
moved with Dynal magnetic concentrator and the cells sus-
pended in 1 ml of 2% FCS/RPMI 1640 medium.
A sample of 106 B cells was suspended in 980 t1 of RPMI 1640
5% FCS medium and 20 d of Fura2-AM (Sigma) dissolved in
DMSO. The final concentration of Fura2 was 4 M. The
mixture was then incubated in a water bath at 37°C for 45
minutes in the dark; the cells were washed and reincubated in
PRMI 5% FCS medium for another 45 minutes at 37°C in the
dark. After this second incubation, the cells were suspended in
solution I containing in mM; NaCl, 127; KCI, 5; MgSO4, 1;
NaH,P04, 1.2; D-glucose, 10; HEPES, 10; CaCI2, 0.02; and
0.1% bovine serum albumin. The measurement of [Ca211 was
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performed with Perkin Elmer fluorescence spectrophotometer
model LS 513 (Perkin Elmer, Norwalk, Connecticut, USA) at
excitation wavelength of 340 and 380 nm and emission wave-
length of 510 nm with a slit of 10 and 20 mm, respectively. An
aliquot of 100 j.d of B cell suspension was added to the
spectrophotometer cuvette containing 1.9 ml of solution II
which is the same as solution I except for its CaCl2 concentra-
tion being 1 m. Autofluorescence from cells and/or added
reagents was monitored during each study and was not found to
be a significant factor. Maximal fluorescence (F max) and
minimal fluorescence (F mm) were evaluated with 0.05% Triton
and 5 mrz EGTA in Tris base buffer (pH 8.0), respectively.
Calculation of [Ca2], was done using the Grynkiewicz equation
[19] and the dissociation constant for Ca2-Fura2 was assumed
to be 225 nM.
Measurement of PTH in blood
PTH was measured with radioimmunoassay utilizing sheep
antisera 478 (supplied by Dr. Claude Arnaud), 1251 labelled
bovine PTH and pooled sera from patients with renal failure as
standard. This antibody reacts predominantely with an immu-
nologic determinant in the carboxyl region of PTH, and it will
detect both the intact hormone and its carboxyterminal frag-
ment. The values of this assay in 63 normal subjects ranged
from undetectable to 15 (5.7 0.7) piEq/ml. The lowest
detectable value was 2 dEq/ml. The blood levels of PTH were
detectable in 33 of the 63 (52%) normal subjects. Elevated blood
levels of PTH were found in all of 60 patients with chronic renal
failure.
Statistical analysis
Student's paired and unpaired t-test was used for statistical
analysis between two groups and one way analysis of variance
and Tukey's HSD test for comparison between multiple groups.
P values below 0.05 were considered significant. Data are
expressed as mean SE.
Results
The blood levels of PTH in dialysis patients (691 114
dEq/ml) were markedly elevated and significantly (P < 0.01)
higher than in normal subjects (5.4 1.2 dEq/ml). Both SAC
and PWM-induced IgG, IgA and 1gM production by B cells
from normal subjects were significantly (P < 0.01) greater than
those by B cells from dialysis patients (Fig. 1).
Table 1 provides the data on the effect of various doses of
PTH on SAC and PWM-induced immunoglobulin production by
B cells from normal subjects and dialysis patients. Both 1-84
PTH (5 x iO M and 10-6 M) and 1-34 PTH (10—6 M) caused
Table 3. Effect of PTH, forskolin, and 8-bromoadenosine 3' ,5'-cyclic monophosphate on SAC or PWM-induced immunoglobulin production
by B cells from normal subjects and dialysis patients
IgG ng/m! IgA ng/ml 1gM ng/ml
Normal % Dialysis % Normal % Dialysis % Normal % Dialysis %
subjects inhibition patients inhibition subjects inhibition patients inhibition subjects inhibition patients inhibition
Studies with SAC (N = 7)
SAC alone
SAC + PTH
SAC + forskolin
SAC + 8-bromoadenosine
3' ,5'-cyclic
monophosphate
200 M
100 LM
Studies with PWM (N = 7)
PWM alone
PWM + PTH
PWM + forskolin
PWM + 8-
bromoadenosine 3' ,5'-
cyclic monophosphate
200 LM
100 LM
1070 736 903 620 1527 741
156 115 218 159 289 165
388 62 699 144 70 451 337 78 598
71 8.9 140 3l 15.0 91" 960 9.3 160
434 58 225 71 181 65 270 52 249 80 370 59
1l3 9.1 60 6.5 230 11.0 9Q 7.4 54 5.8 1220 10.0
468 56 274 63 416 55 331 47 626 59 289 61
1420 13.3 360 5.0 120 12.7 620 10.1 112 7.2 490 6.6
499 53 298 67 519 43 370 41 529 65 320 57
1390 13.0 440 5.5 118 13.3 9o 14.5 1470 9.6 440 6.0
1211 832 1376 680 955 759
209 170 333 159 126 110
810 30 839 364 68 584 445 64.0 643
1100 9.0 169 950 8.0 110 1o2 8.2 115
591 49 453 39 434 65 325 52 260 77.4 461 38
1290 10.0 8.1 2100 11.3 58 15.1 iooa 9.9 1330 14.9
375 69 360 57 479 65 331 47 298 72 288 62
700 5.8 670 8.1 860 6,1 53 8.6 560 5.6 360 4.8
346 71 384 54 452 67 334 46 287 70 353 54
75 6.2 930 11.2 880 6.4 540 8.7 630 6.6 690 9.0
Data are presented as mean SE. There were no significant differences between the % inhibitions of immunoglobulin induced by PTH, forskolin,
or 8-bromoadenosine 3',5' monophosphate in the normal subjects, between those induced in dialysis patients, or between those induced by
forskolin or 8-bromoadenosine 3',S' monophosphate in normal subjects and dialysis patients as evaluated by one-way analysis of variance and
Tukey's HSD test for comparison between groups.
0 P < 0.01 (by paired 1-test) from SAC alone or PWM aloneb P < 0.05 (by paired 1-test) from SAC alone or PWM alone
Fig. 3. Effects of 1-84 PTH (5 X io- M) and of A23187 (0.5 M) on
SAC or PWM-induced immunoglobulin production by B cells from
normal subjects. Symbols are: (0) mitogen; (•) mitogen + PTH; ()
mitogen + A23187. Each column represents mean value of 6 studies
conducted simultaneously, brackets denote 1 SE. *D < 0.01 vs. mitogen
only, #P < 0,01 vs. mitogen and PTH,
IgG gA gM
significant inhibition of SAC-induced (P < 0.01) and PWM-
induced (P < 0.05 to <0.01) immunoglobulin production by B
cells from normal subjects. In contrast, only the higher doses of
10_6 M of 1-84 PTH produced significant (P < 0.05 to <0.01)
inhibition of SAC but not of PWM-induced immunoglobulin
production by B cells from dialysis patients. The dose of 5 x
i0 M of 1-84 PTH that inhibited IgG, IgA and 1gM production
by B cells from normal subjects had no inhibitory effect on
immunoglobulin synthesis by B cells from dialysis patients.
Inactivation of 1-84 PTH abolished its inhibitory effect on both
SAC and PWM-induced IgG, IgA and 1gM production by B
cells from normal subjects (Fig. 2).
Table 2 gives the data on the effect of 5 X lO M 1-84 PTH
on SAC and PWM-induced production of 1gM by B cells from
normal subjects when the hormone was added either at the
beginning or at day 2 of the culture. The production of 1gM
induced by both mitogens was significantly inhibited (P < 0.01)
only when the hormone was added at the beginning of the
culture. This inhibitory effect was not observed in studies in
which the hormone was added at day 2 of the culture.
Table 3 shows the data on the effect of 5 x l0— M 1-84 PTH,
20 ng/ml forskolin and 100 or 200 .tM of 8-bromoadenosine 3',S'
cyclic monophosphate on SAC and PWM-induced immuno-
globulin production by B cells from normal subjects and dialysis
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Fig. 4. Effects of 1-84 PTH (5 X io- M) and of A23l87 (0.5 M) on
SAC or PWM-induced immunoglobulin production of B cells from
dialysis patients. Each column represents mean value of 6 (SAC) or 7
(PWM) studies conducted simultaneously. Brackets denote I SE.
0.01 vs. mitogen and PTH.
*
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Table 4. Effect of 1-84 PTH and of cholera toxin on SAC or PWM-induced immunoglobulin
dialysis patients
production by B cclis from normal subjects and
IgG ng/ml IgA ng/ml 1gM ng/ml
Normal % Dialysis % Normal % Dialysis % Normal % Dialysis %
subjects inhibition patients inhibition subjects inhibition patients inhibition subjects inhibition patients inhibition
Studies with SAC
(N = 5—7)
SAC alone 817
109
693
103
945 820
168 252
1244
223
904
128
SAC + PTH 496
70
39 597
4.2 121
591 37 773
l22 6.2 182
655
l48
48 853
6.6 112
SAC + cholera toxin 465
58
41 506
9.3 121
32 573 33 614
10.6 40 8.2 167C
25
10.3
631
81
41 610
13.3 l30
33
9.6
Studies with PWM(N = 5—7)
PWM alone 1180
151
730
247
1341 927
184 151
1194
147
651
217
PWM + PTH 746
97
36 624
4.8 208
770 33 815
83 6.9 307
469
69
61 546
2.3 228
PWM + cholera toxin 726
44b
35 496
6.7 203C
40 713 46 604
9.6 185 3.5 234"
41
7.3
578
83
52 380
3.3 221k
60
21.3
Data are presented as mean SE. There were no significant differences between % inhibitions of amount of immunoglobulin produced induced
by PTH and cholera toxin in normal subjects, by cholera toxin in dialysis patients, or by cholera toxin in normal subjects and dialysis subjects as
evaluated by one-way analysis of variance with Tukey's HSD test for comparison between groups.
a P < 0.01 vs. mitogen aloneb P < 0.02 vs. mitogen alone
c P < 0.05 vs. mitogen alone
patients. Again this dose of PTH produced significant (P < 0.01)
inhibition of IgG, IgA and 1gM production by B cells from
normal subjects but failed to exert an inhibitory effect on
immunoglobulin production by B cells from dialysis patients. In
contrast, both forskolin and 100 or 200 pM of 8-bromoadenosine
3',S' cyclic monophosphate caused significant (P <0.01) inhi-
bition of immunoglobulin production by B cells from both
normal subjects and dialysis patients. There were no significant
differences in the degree of inhibition of immunoglobulin pro-
duction induced by forskolin or 8-bromoadenosine 3' ,5' cyclic
monophosphate by B cells from both normal subjects or dialysis
patients.
Table4 provides the data on the effect of 1-84 PTH or cholera
toxin on SAC or PWM-induced immunoglobulin production by
B cells from normal subjects and dialysis patients. Again, PTH
or cholera toxin produced significant inhibition of all immuno-
globulin production by B cells from normal subjects, but only
cholera toxin caused significant inhibition of immunoglobulin
production by B cells from dialysis patients. There was no
significant difference between the % inhibition of immunoglob-
ulin production induced by PTH or cholera toxin by B cells
from normal subjects or between the inhibition by cholera toxin
in B cells from normal or uremic subjects.
A dose response study with various concentrations of A23 187
calcium ionophore showed that 0.5 /.LM produced the greatest
inhibition of immunoglobulin production. 1gM production with
SAC by B cells from normal subjects was 790 133 nglml, and
the values with SAC and A23 187 calcium ionophore in concen-
tration of 0.05, 0.10, 0.25 and 0.50 M were 842 90, 591 204,
301 170 and 95 16 ng/ml. In order to exclude the possibility
that 0.5 /.M ofA23187 calcium ionophore is toxic to B cells, we
examined cell viability with Trypan blue exclusion test before
and after 24 hr incubation; the values of cell viability were 96
1.3 versus 94 1.0%. Figures 3 and 4 depict the effect of 0.5 jM
of A23 187 calcium ionophore on SAC and PWM-induced IgG,
IgA and 1gM production by B cells from normal subjects and
dialysis patients, respectively. The A23187 calcium ionophore
caused significant (P < 0.01) inhibition of all immunoglobulin
production by B cells from both normal subjects and dialysis
patients. There were no significant differences in the degree of
the inhibition of immunoglobulin production by B cells from
both normal subjects and dialysis patients.
Figure 5 shows tracings of fluorescence emission of Fura 2 at
510 nm emission wavelength in response to 340 and 380 nm
excitation wavelength along with Triton and EGTA calibration
during the measurement of [Ca2] in B cells from a normal
subject and a dialysis patient. The resting levels of [Ca2i, in
this study was 80 nm in the normal subjects and 110 nm in the
dialysis patient. The values of resting levels of [Ca211 in B cells
of 11 dialysis patients (115 5.2 nM) were significantly (P <
0.01) higher than those in B cells from 11 normal subjects (86
4.4 n, Fig. 6).
Discussion
Previous studies from our laboratory have demonstrated that
B cells are target for PTH action [12]. Both the intact molecule
of the hormone and its aminoterminal fragment inhibited pro-
liferation of B cells from normal subjects. The results of the
present study extend these observations and demonstrate that
1-84 and 1-34 PTH inhibits both SAC and PWM-induced IgG,
IgA and 1gM production by B cells from normal subjects. This
inhibitory effect is most likely related to the biological activity
of the hormone and not to a contaminant in the hormone
preparation, since it is exerted by the synthetic 1-34 PTH and it
is abolished by the inactivation of the 1-84 PTH.
The high dose of PTH required for its in vitro effect on
immunoglobulin production may raise doubt about the physio-
logical relevance and/or significance of such an action. It is of
0.05% Triton
5 mvi EGTA
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Normal subject Dialysis patient
Fig. 5. Sample tracing offluorescence of Fura 2 at 510 nm wavelength
emission in response to 340 and 380 nm wavelengths excitation along
with Triton and EGTA calibration. Continuous fluorescence depicts
excitation at 340 wavelength nm and interrupted fluorescence at the
bottom of the figure shows excitation at 380 nm wavelength. The levels
of cytosolic calcium were 88 nm in B cells of the normal subject and 125
nm in B cells of the dialysis patient.
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interest, however, that most of the in vitro actions of PTH on
cells that are not traditional targets for the hormone such as the
heart cells [20], polymorphonuclear leukocytes [21], pancreatic
islets [17] or muscular smooth muscle cells [221 also required a
high dose of the hormone. Several reasons may explain such a
phenomenon without necessarily excluding a physiological sig-
nificance of such non-traditional actions of PTH. First, it is
possible that many of these cells may have a proteinase
attached to their surfaces or they may generate a proteolytic
enzyme during their isolation and preparation. Such enzymes
may degrade or inactivate the hormone and hence higher doses
are needed for its in vitro action. Indeed, Bialasiewicz et al [13]
found that surface membranes of B cells have enzymatic
activity capable of fragmenting bovine PTH. This is not sur-
prising since Tokes [23] demonstrated a neutral proteinase
attached to the outer surface of the plasma membrane of the
rodent B lymphocytes. Further, Barling, Cartmell and Scott
[24] reported that a neutral proteinase located on the surface of
human leukocytes is capable of degrading bovine 1-84 PTH.
Second, these actions of PTH may not be mediated by a
hormone-receptor interaction, and hence require large amounts
of the hormone. This seems unlikely since PTH stimulated
cAMP production by many of these cells including myocardial
cells [20], pancreatic islets [25], and human T cells [26] and B
cells [12]. Third, it is also possible that these non-traditional
actions of the hormone are mediated by interaction with specific
PTH receptors that may be present at low concentration or may
have low affinity and therefore, require higher amount of PTH.
The mechanisms responsible for the inhibition of immuno-
globulin production by PTH are not fully elucidated by our
studies and several processes may be involved. Antigenic
stimulation of B cells causes proliferation of these cells fol-
lowed by their differentiation into antibody forming cells; these
processes proceed under the influence of lymphokines pro-
duced by the T cells [27]. Therefore, the inhibitory effect of
PTH on immunoglobulin production by B cells could be medi-
ated by an action of the hormone on one or more of the steps
involved in these processes.
First, we have already shown that PTH inhibits B cell
proliferation [12]. It is of interest that the present study showed
that the inhibition of immunoglobulin production was observed
only when PTH was added at the beginning of the culture, that
is, at the stage of initiation of proliferation. However, it should
be mentioned that 1gM production on days 4 and 6 after the
addition of PTH was inhibited by 78% and 73%, respectively;
this degree of inhibition was greater than the 55% of PTH-
induced inhibition of B cell proliferation on day 5 of culture
previously reported by us [12]. Thus it appears that the inhibi-
tion of immunoglobulin production by PTH is not entirely due
to the inhibition of B cell proliferation but could also be due in
part to an effect on B cell maturation and differentiation.
Second, we have previously shown that 1-84 PTH stimulated
PHA-induced T cell proliferation and interleukin-2 production
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denote mean and SE.
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by these cells [26]. It would be difficult to propose that PTH
stimulates production of one lymphokine (interleukin-2) and at
the same time inhibits the production of others (interleukin-3 to
-6), which are involved in B cell maturation and immunoglob-
ulin production [27—33]. Third, available data indicate that
cAMP inhibits both proliferation of B cells and their production
of immunoglobulins [34—36]. We have previously demonstrated
that PTH stimulates cAMP production by human B cells [12],
and the present study demonstrated that agents which cause an
increase in cAMP content of the B cells (forskolin or cholera
toxin) as well as the application of the cyclic AMP analogue
(8-bromoadenosine 3',5' cyclic monophosphate) inhibit immu-
noglobulin production by B cells. It is, therefore, plausible to
suggest that PTH mediates its inhibitory action on the produc-
tion of immunoglobulin through the stimulation of cAMP gen-
eration. However, it should be mentioned that the mechanism
through PTH stimulates cAMP production by B cells is not as
yet defined; the hormone may act on G proteins or adenylate
cyclase directly or may interfere with phosphodiesterase activ-
ity. Fourth, several studies have shown that PTH enhances
entry of calcium into many cells [20, 25, 37—41] and such an
acute action on B cells may contribute to the inhibition of
immunoglobulin production. Although we do not have a direct
evidence to support such an effect, our finding that the calcium
ionophore A23 187 inhibited immunoglobulin production by B
cells from both normal subjects and dialysis patients provides
indirect support for the proposition that acute rise in cytosolic
calcium into B cells contributes to the inhibition of immuno-
globulin production.
Our studies also showed that the magnitude of both SAC or
PWM-induced stimulation of immunoglobulin production by B
cells from dialysis patients is significantly (P < 0.01) smaller
than that by B cells from normal subjects. This observation is
similar to that observed by others [3, 4, 6, 8]. The mechanisms
underlying this phenomenon are not evident. It is possible that
it is related to the state of secondary hyperparathyroidism. It
has been shown that chronic exposure to PTH in the presence
or absence of chronic renal failure is associated with an increase
in the resting levels of [Ca2i of many cells such as pancreatic
islets [42, 43], brain synaptosomes [44], polymorphonuclear
leukocytes [45], platelets [46, 47], and T cells [48]. Such a
chronic elevation in the resting levels of [Ca2]1 of these cells
was associated with disturbances in their function [42—48]. It is
tempting to propose that the chronic exposure of B cells from
dialysis patients to excess PTH elevated their resting levels of
[Ca2] which, in turn, would adversely affect their ability to
produce immunoglobulins. Such an action may be mediated by
pathways different from those affected by an acute rise in
cytosolic calcium. This proposition remains tentative at present
time. A definite proof could be provided by examining the
resting levels of [Ca211, and immunoglobulin production by B
cells from dialysis patients with and without excess PTH. This
is difficult to achieve since total or subtotal parathyroidectomy
is not performed frequently nowadays. Further, suppression of
the parathyroid gland activity with 1,25 (OH)2D3 does not
usually achieve normal blood levels of PTH, and such a therapy
would introduce the issue of whether this vitamin D metabolite
by itself could affect B cell function. It appears that an animal
model of chronic renal failure with and without excess PTH
would be the most appropriate approach to answer this ques-
tion. Also, studies are needed to delineate the cellular pathways
through which a sustained elevation in [Ca2] interferes with
immunoglobulin production.
It is interesting that 5 x l0— M 1-84 PTH did not inhibit SAC
or PWM-induced immunoglobulin production by B cells from
dialysis patients as it did in the B cells from normal subjects.
Further, the higher dose of PTH (10—6 M) inhibited SAC but not
PWM-induced immunoglobulin production. These observations
indicate that the chronic exposure of the B cell to excess PTH
in dialysis patients is associated with reduced responsiveness to
exogenous PTH. This is not surprising since other observations
have also demonstrated resistance to the action of PTH on its
target organs in chronic renal failure. We have previously
shown that the magnitude of the inhibition of proliferation of B
cells from dialysis patients by PTH is less than that in B cells
from normal subjects [12]. Also patients with moderate or
advanced chronic renal failure and those treated with dialysis
display resistance to the calcemic action of PTH [49, 50], and
this resistance has been attributed to desensitization or down-
regulation of PTH receptors in bone as a consequence to the
elevation of blood levels of PTH [51]. It is possible that a similar
phenomenon may be operative in interaction between PTH and
B cells in dialysis patients. However, definite proof of this
proposition requires direct measurement of PTH receptors.
Down-regulation of PTH receptors in B cells from dialysis
patients would be associated with a lesser production of cyclic
AMP by the hormone. Since cyclic AMP inhibits SAC or
PWM-induced immunoglobulin production [34-36], one would
expect that PTH may fail to inhibit immunoglobulin production
by B cells from dialysis patients. Unfortunately, we could not
measure PTH-induced cyclic AMP generation by B cells from
dialysis patients since the amount of blood needed to isolate
adequate amount of pure B cells for such measurements ex-
ceeds 100 ml. We did not feel that it is ethical to ask dialysis
patients for such a blood letting. It is interesting, however, that
both forskolin and cholera toxin that do not require receptor
interaction for stimulation of cyclic AMP generation as well as
the cyclic AMP analogue, 8-bromoadenosine 3' ,5' cyclic mono-
phosphate, significantly inhibited SAC or PWM-induced immu-
noglobulin production by B cells from dialysis patients. These
observations are consistent with the proposition that the failure
of PTH to inhibit SAC or PWM-induced immunoglobulin pro-
duction by B cells from dialysis patients is due, at least in part,
to its inability to generate an adequate amount of cyclic AMP as
a result of the down-regulation of the PTH receptors in B cells.
The results of the present study and those previously re-
ported from our laboratory [12], demonstrating adverse effects
of PTH on B cell proliferation and on their immunoglobulin
production, are consistent with the notion that state of second-
ary hyperparathyroidism of chronic renal failure plays a role in
the genesis of the disturbed humoral immunity of such patients.
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